Will BRINSUPRI generate $1B+ in net revenue for FY2026?

Achieving $1B in FY2026 requires averaging $250M/quarter from a Q4 2025 base of $144.6M. This implies the H2 2026 run rate must reach $300M+ per quarter. While the launch is exceptional, historical rare disease comps show very few drugs reach $1B in their first full calendar year. The analyst consensus midpoint near $1B is driven partly by optimism about the TAM size. Gross-to-net trajectory and prescriber depth expansion are the key variables. The 73% annual growth requirement from Q4 annualized is achievable but demanding.

The math is demanding: Q1 ~$190-210M, Q2 ~$230-250M, Q3 ~$260-280M, Q4 ~$290-310M would get to ~$1B. Each quarter requires sustained 15-20% sequential growth. The Q1 deductible headwind makes the early quarters harder. If Q1 comes in at $190M rather than $210M, the remaining quarters need to compensate with ~$270M average, which pushes each to near the $300M mark. The margin for error is thin. The single-product dependency and prescriber depth concerns add risk to sustained acceleration.

The strongest argument for $1B+ is the oral formulation advantage in a monopoly market. BRINSUPRI is the only approved therapy for bronchiectasis, an area with 300-500K US patients and massive unmet need. Prescriber expansion from 4,000 to potentially 6,000-8,000 by year-end, combined with deepening repeat rates, creates a compounding revenue driver that historical rare disease launches without these characteristics didn't have. The base rate for first-in-class monopoly oral drugs in significant unmet need is higher than the general rare disease base rate.

The $1B threshold is psychologically and analytically important but the mathematical requirements are stringent. The annualized Q4 run rate of ~$578M needs to nearly double. While rare disease launches can show this acceleration, the base rate for achieving $1B in the first full calendar year is below 10%. Even adjusting for first-in-class monopoly status (perhaps 25-35%), the probability remains below coin-flip. The GTN trajectory and Q1 seasonal effect create additional downside risk to the cumulative annual total.

Consensus estimates clustering around $900M-$1.1B suggest analysts view $1B as the central tendency, not the upside case. If this is the consensus base case, the probability of achieving it should be modestly below 50% (consensus estimates are typically met ~45% of the time, with roughly equal probability of beat and miss). The analysis flags EXPECTATIONS_PRICED as AGGRESSIVE, reinforcing that the market already needs this outcome.

The most concerning factor is the back-loaded nature of the required revenue trajectory. If Q1 disappoints (say $185M), achieving $1B requires the remaining three quarters to average $272M — which means Q4 would need to approach $320M. This assumes no setbacks from payer pushback, no safety signals, and continued prescriber expansion. The probability should discount the compounding risk of multiple quarters of required execution.

First-in-class oral monopoly in large unmet need supports aggressive ramp. Analyst consensus near $1B suggests achievability. But the mathematical requirements are stringent — 73% annual growth from Q4 annualized rate — and base rates for $1B in first full year are low. Near coin-flip, slightly below.

The tension between the exceptional launch and the demanding $1B threshold resolves slightly bearish. Q1 seasonality, prescriber depth uncertainty, and GTN trajectory all create downside risk to the cumulative annual number. More likely to land in $850M-$950M range than exceed $1B.

The strong launch provides a solid foundation, but $1B requires sustained acceleration that few drugs achieve in their first full year. The combination of demanding math, seasonal headwinds, and aggressive market expectations creates a scenario where $1B is plausible but not probable.